Genomics
A de-risked HAE asset (lonvo-z, 87% attack cut, BLA filing) wrapped in a financing-and-competition problem — the cure is real, the question is whether anyone buys a one-shot in a market with 11 approved drugs, and whether a $1.9B-cap, 38%-shorted clinical-stage burner reaches launch without another dilutive raise.
Research
The verdict
A de-risked HAE asset (lonvo-z, 87% attack cut, BLA filing) wrapped in a financing-and-competition problem — the cure is real, the question is whether anyone buys a one-shot in a market with 11 approved drugs, and whether a $1.9B-cap, 38%-shorted clinical-stage burner reaches launch without another dilutive raise.
Intellia is a Cambridge, MA clinical-stage biopharma founded 2014, pioneering in vivo CRISPR/Cas9 genome editing — editing the gene inside the patient's body (via a single IV infusion of a lipid-nanoparticle-delivered CRISPR payload that homes to the liver), rather than the ex vivo approach (extract cells, edit in a dish, re-infuse) that Vertex/CRISPR Therapeutics' Casgevy uses. This is the company's whole identity: "the first company to advance in vivo genome editing product candidates into Phase 3 clinical development".
The two lead assets are the company:
How it makes money — today, it doesn't. "All of our revenue to date has been collaboration revenue". FY2025 collaboration revenue was $67.7M, essentially all from Regeneron cost-reimbursement and milestone recognition, not product sales. The business model is: burn cash advancing assets → get lonvo-z approved (first product revenue targeted H1 2027) → build a commercial gene-editing franchise.
Key counterparties. Customers: none yet (pre-commercial). Partner: Regeneron (the material relationship — see Lens 3). Suppliers: contract manufacturers (CMOs/CDMOs) for the LNP + guide-RNA + Cas9 mRNA components — in vivo CRISPR products are "novel, complex and difficult to manufacture" per the company's own first-listed risk factor. IP licensors: Caribou Biosciences (foundational CRISPR/Cas9 in-license sublicensing UC/Vienna/Charpentier rights).
Commercial-layer files for genomics are missing (kb/genomics/wiki/supply-chain.md not present), so this is reconstructed from the 10-K.
Upstream → Intellia → patient:
IP layer (the true upstream). The CRISPR/Cas9 right-to-operate originates with the Regents of the University of California + University of Vienna + Emmanuelle Charpentier (the "UC/Vienna/Charpentier" foundational patent family), which Intellia accesses via an exclusive sublicense from Caribou Biosciences (July 2014 Caribou License). Intellia owes Caribou low-to-mid single-digit royalties. This is a single-source chokepoint with a live legal cloud — the competing Broad Institute patent family (MIT/Harvard) has been in interferences/challenges against the UC/Vienna camp for a decade. If Broad prevails on the relevant claims, Intellia's freedom-to-operate on therapeutic CRISPR could require additional licensing.
Manufacturing inputs. Three physical components — (a) the guide RNA (targets KLKB1 or TTR), (b) Cas9 mRNA (the editing enzyme), (c) the lipid nanoparticle (LNP delivery vehicle). Produced by third-party CMOs. Single-source/scale-up risk is explicitly flagged as a top risk factor. Chokepoint: LNP manufacturing at commercial scale for a systemically-dosed product is non-trivial.
Clinical/distribution layer. CROs run MAGNITUDE/MAGNITUDE-2/HAELO; for ATTR, Regeneron is the co-development partner and shares ~25% of worldwide development costs. The Regeneron Genetics Center + proprietary mouse models feed target discovery.
End customer. Patients via specialty/hospital outpatient infusion (single IV). Payers (commercial + Medicare) are the real economic buyer — and for a one-time high-list-price gene therapy, the reimbursement/contracting path (annuity vs. one-time payment) is the load-bearing unknown.
Named chokepoints: (1) the Caribou/UC-Vienna IP single-source with Broad overhang; (2) commercial-scale LNP/Cas9 manufacturing; (3) Regeneron as the sole material partner on the larger of the two assets.
The real moat is being first and platform breadth in in vivo editing. Intellia is the only company with systemic in vivo CRISPR editors in Phase 3. That is a genuine technical lead — Casgevy (Vertex/CRSP) is ex vivo (harder, more expensive, requires myeloablation); Intellia's "one IV infusion, outpatient" profile is structurally superior if the safety holds. The modular platform (swap the guide RNA, keep the LNP+Cas9 chassis) means each new liver target is cheaper/faster than the last — a process moat.
Bargaining power: weak-to-moderate, and asymmetric.
The moat's soft underbelly: durable biology (a real cure) is the asset, but commercial durability is unproven. Per BioPharma Dive's framing of the HAE setup: "genetic medicines have struggled to sell in areas where, as with HAE, multiple effective medicines already exist". A scientific moat is not a commercial moat.
One segment. "The Company has identified one operating and reportable segment: the development of gene editing-based therapies. All of the Company's material assets are held in the United States and all of the Company's collaboration revenue has been generated in the U.S.". The CODM (the CEO) manages on a consolidated net-loss basis. segments.csv is header-only, consistent with single-segment reporting.
The meaningful "segmentation" is by program (external development spend, Q1-2026 vs Q1-2025):
| Program | Q1-2026 ext. dev. | Q1-2025 ext. dev. | YoY |
|---|---|---|---|
| nex-z (ATTR) | $20.2M | $23.1M | −12% |
| lonvo-z (HAE) | $8.1M | $10.7M | −24% |
Spend is down across both leads — the trend is deliberate deceleration of cash burn ("we expect our research and development expenses to decrease … as we focus resources on high value programs"), offset by rising commercial-buildout G&A. nex-z remains ~2.5× the lonvo-z external spend, reflecting the much larger ATTR Phase 3 (MAGNITUDE = ~1,200 patients vs HAELO's 80).
Revenue by collaboration (FY2025): Regeneron 2016/2020/2024 agreements $20.8M; ATTR Co/Co cost-reimbursement $31.9M; SparingVision termination $9.0M one-time; remainder smaller LCAs (AvenCell, Kyverna, ONK).
| Program | Indication | Mechanism / modality | Phase | Next catalyst (date) | PoS (subjective) |
|---|---|---|---|---|---|
| lonvo-z | HAE | In vivo CRISPR knockout of KLKB1 (liver), LNP-delivered, one-time IV | Phase 3 complete — positive; rolling BLA | Complete BLA submission H2 2026; potential US launch H1 2027 | High (~80%+ approval, post-positive P3) |
| nex-z (ATTR-CM) | ATTR cardiomyopathy | In vivo CRISPR knockout of TTR | Phase 3 (MAGNITUDE), ~1,200 pts; hold lifted Mar 2026 | Enrollment ongoing; CV-event readout multi-year | Medium — efficacy strong, safety scrutiny |
| nex-z (ATTRv-PN) | hereditary ATTR polyneuropathy | In vivo CRISPR knockout of TTR | Phase 3 (MAGNITUDE-2), 50 pts; hold lifted Jan 2026 | Complete enrollment H2 2026; mNIS+7 at month 18 | Medium |
lonvo-z / HAELO — the de-risking event (April 2026). Global, randomized, double-blind, placebo-controlled; 80 patients enrolled (Type I/II HAE), one-time 50 mg dose. Met primary endpoint: 87% reduction in HAE attacks vs placebo (weeks 5–28), mean monthly attack rate 0.26 (lonvo-z) vs 2.10 (placebo), p<0.0001. All key secondaries hit (p<0.0001), including 62% of lonvo-z patients entirely attack-free AND therapy-free vs 11% placebo. Safety: most common TEAEs were infusion-related reactions, headache, fatigue; all TEAEs Grade 1–2, no serious adverse events in the lonvo-z arm as of the Feb 10 2026 cutoff.. Additional data presented at EAACI 2026, published in NEJM.
nex-z — strong efficacy, a safety scar. Phase 1 ATTR-CM (36 pts, Aug 2025 cutoff): mean serum TTR reduction 87% at 36 months (n=9); a matched-cohort post-hoc showed all-cause mortality 3.9 vs 12.7 per 100 patient-years (≈73% lower risk). ATTRv-PN Phase 1: 92% mean TTR reduction at 24 months, published NEJM. But on Oct 29 2025 the FDA placed clinical holds on both MAGNITUDE INDs after a Grade 4 liver transaminase + bilirubin event in a MAGNITUDE patient; that patient died Nov 5 2025 (PI-reported cause: septic shock from a perforated duodenal ulcer, with acute liver injury in the course). Holds lifted Jan 27 2026 (PN) and Mar 2 2026 (CM) with mitigation: enhanced liver-lab monitoring, short-course steroids if transaminases rise, exclusion of patients with certain liver abnormalities.
The asset table is the company: lonvo-z is the near-term value driver; nex-z is the bigger TAM but carries the live safety question.
No transcripts on disk (transcripts/ empty); reconstructing tone from filings + press flow.
Tone arc over the last ~18 months has swung hard, twice. (1) Late 2023–2024: defensive contraction — two consecutive January layoffs (15% Jan 2024, 27% Jan 2025) and explicit "challenging market environment" language; management pivoted from a broad platform story to "focus resources on high value programs … efficient execution". (2) Oct–Nov 2025: crisis — the clinical hold + patient death. (3) Q1 2026 → now: cautious recovery — holds lifted, then the HAELO win, then rolling BLA + an opportunistic $194.6M raise. The recurring phrases now are "high value programs," "commercial buildout," "efficient execution," "prepare for launch." What they stopped saying: the expansive multi-organ / multi-target platform narrative of the 2021 peak — that vocabulary is gone, replaced by lead-asset discipline. Management overview still opens "a leading biopharmaceutical company … revolutionizing medicine leveraging CRISPR", but the body is all execution and runway.
Catalyst calendar (de-risk / kill events):
| When | Event | Why it matters |
|---|---|---|
| H2 2026 | Complete lonvo-z BLA submission to FDA | Locks the regulatory clock toward H1-2027 launch |
| H2 2026 | Complete MAGNITUDE-2 (ATTRv-PN) enrollment | De-risks the smaller ATTR arm; pace signals hold-recovery health |
| 2026 (ongoing) | Longer-term nex-z safety data post-hold | Any new Grade ≥3 liver event re-opens the existential question |
| H1 2027 | Potential lonvo-z US launch (first revenue ever) | The whole "can a one-shot sell" thesis goes live |
| Multi-year | MAGNITUDE (ATTR-CM) CV-event readout | The big-TAM binary; partnered with Regeneron |
Mechanism comps (not P/E — this is pre-revenue). Two competitive battlefronts:
Comps — sector market structure (valuation context, not multiples):
| Company | Ticker | Mkt cap | Cash (Q1-26) | Stage | Source |
|---|---|---|---|---|---|
| CRISPR Therapeutics | CRSP | ~$4.76B | $2.44B | Approved (Casgevy, $43M Q1 rev) | |
| Beam Therapeutics | BEAM | ~$2.52B | $1.2B | Clinical (base editing) | |
| Intellia | NTLA | ~$1.92B | $517.2M (+$194.6M Apr raise) | Clinical, BLA filing | / |
| Editas Medicine | EDIT | n/a | n/a | Clinical, no approval |
EV/Sales, EV/EBIT, P/E, dividend yield, 5-yr ROE: n/a — not applicable (pre-revenue, no earnings, no dividend; all four peers are loss-making clinical-stage except CRSP which is barely-commercial). NTLA trades at the smallest cap of the named CRISPR set despite having the only systemic-in-vivo Phase-3 assets — the market is discounting execution + dilution risk, not the science.
NTLA is a pure catalyst/sentiment stock — it has no earnings to beat, so it moves on clinical data, FDA actions, financings, and macro biotech risk appetite. Five-year tape:
Pattern: the market reacts to (1) lead-asset clinical reads, (2) FDA hold/approval actions, (3) financing dilution, and (4) macro biotech beta. Safety events are the most violent down-moves; positive Phase 3 is the most reliable up-move. 38% short interest means any clean catalyst can squeeze and any miss can cascade — it is a battleground stock.
CEO: John M. Leonard, M.D. (age 67), President & CEO since January 2018.
Acting as a forensic analyst. For a pre-revenue biotech, the income statement is mostly expense, so the forensic surface is narrower and cleaner than an operating company — the risks live in cash burn, collaboration-revenue recognition, SBC, and going-concern.
Regulatory findings (required sub-section).
EPS for the next three fiscal years — these are losses, and the number to watch is burn, not EPS. Building bottom-up from FY2025 actuals + guidance:
rNPV intuition (lead asset, lonvo-z). HAE addressable population is modest (rare disease, ~tens of thousands US/EU), and lonvo-z must convert prophylaxis patients to a one-time product against 11 competitors. Rough sketch: if lonvo-z reaches $300–500M peak sales, at ~80% post-P3 PoS and a 12% discount, the risk-adjusted contribution is on the order of a few hundred million to ~$1B of present value — i.e. lonvo-z alone roughly underwrites the current ~$1.9B EV, leaving nex-z (the much larger ATTR TAM) as the call-option upside — but nex-z carries the live liver-safety question, so the market is (rationally) assigning it a steep risk discount. Peak-sales × PoS × discount inputs are all ``; no sell-side rNPV was sourced (n/a).
Runway-to-catalyst — the actual decision variable, and it's adequate (barely). Cash $517.2M (Mar 31 2026) + $194.6M April raise ≈ ~$712M pro-forma, plus Regeneron cost-reimbursement. Management guidance: funds operations "at least into 2028" — i.e. runway reaches the lonvo-z launch (H1 2027) and the next nex-z value inflections. At ~$385M annual burn, ~$712M is roughly 1.8 years of pure runway, consistent with the "into 2028" guide. Verdict on runway: it reaches the BLA approval + launch, but NOT comfortably through a slow launch + the multi-year MAGNITUDE CV readout — another raise (ATM or follow-on) before profitability is near-certain. The $368.5M open ATM is the pre-positioned tool.
Brier forecast (binary catalyst, not EPS): "NTLA — FDA accepts the lonvo-z BLA for review by 2027-06-30," p≈0.85. (Not logging via forecast.ts — breadth/watchlist loop.)
Bull case. Intellia owns the only systemic in vivo CRISPR assets in Phase 3, and lonvo-z just worked — 87% attack reduction, 62% attack-and-therapy-free, no SAEs. A clean BLA → H1-2027 launch makes Intellia a commercial gene-editing company, re-rating it out of the binary-clinical bucket. nex-z is a potential first one-time cure for ATTR — a multi-billion-dollar TAM where the incumbent (tafamidis) already does $5.4B/yr — and Phase 1 efficacy (87–92% TTR knockdown, 73% lower mortality vs matched cohort) is best-in-class biology. The platform is modular: every new liver target is cheaper than the last. Regeneron validates the tech and funds ~25% of ATLA's biggest program. At ~$1.9B cap — below both CRSP and BEAM — with the only in-vivo Phase-3 readouts, the science is being given away. 38% short interest is squeeze fuel on any clean catalyst.
Bear case (the 2–3 things that could permanently impair).
Pre-mortem (it's Dec 2027, the thesis broke). Most likely story: lonvo-z got approved but the launch curve was flat — payers balked at one-time pricing, physicians defaulted to familiar Orladeyo/Takhzyro, and conversion was a trickle; meanwhile a fresh nex-z liver signal in MAGNITUDE forced a second hold. Cash ran toward empty, forcing a deeply dilutive raise at a low price. The stock is back near its lows not because the science failed but because the commercial and financing model did.
Are multiples too high? No conventional multiple applies (pre-revenue). On EV vs sourced-science, NTLA is the cheapest of the named CRISPR set — the market is pricing commercial + dilution + nex-z-safety risk, not doubting the biology.
Contrarian view (what the market refuses to see). The consensus treats NTLA as "another cash-burning gene-editing lottery ticket" and shorts it at 38%. The contrarian read: lonvo-z is already de-risked clinically and the BLA is a formality — the bet is no longer "does it work" but "does a de-risked rare-disease asset + adequate runway-into-2028 + the only in-vivo platform deserve the smallest cap in the peer set?" If the launch merely doesn't fail, the re-rate from $1.9B is asymmetric. The market is conflating clinical risk (largely resolved for lonvo-z) with commercial risk (real but bounded).
Dismantling the bull case as a skeptical short:
A David Liu-pedigreed prime-editing pioneer cornered into a defensive crouch — 25% RIF, founder-CEO out, lead CGD asset demoted to a partnering candidate, going-concern doubt at ~14 months of cash, and an existential Beam IP arbitration over one of its two surviving lead programs. At a ~$537M cap it is a deeply discounted binary call option on 2027 first-in-human liver data; bullish only for risk-seeking capital that can survive a dilution-or-bust 2026.
A real long-read/native-modification monopoly inside a structurally hard razor-and-blade model — but the market has stopped paying for "deep tech that takes 10 years"; down 73% from IPO, near 52-week lows, it is a show-me story where 2027 EBITDA breakeven (twice-pushed) is the entire thesis, and the new ex-Danaher CEO either professionalizes the commercial engine or the optionality stays un-priced.